-
Je něco špatně v tomto záznamu ?
Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds
A. Machara, V. Lux, M. Kožíšek, K. Grantz Šašková, O. Štěpánek, M. Kotora, K. Parkan, M. Pávová, B. Glass, P. Sehr, J. Lewis, B. Müller, HG. Kräusslich, J. Konvalinka,
Journal of medicinal chemistry.
2016 ;
59 (2) :
545-58.
[pub] 20160106
Jazyk angličtina Země Spojené státy americké
Typ dokumentu časopisecké články, práce podpořená grantem
Perzistentní odkaz
https://www.medvik.cz/link/bmc16020081
- MeSH
- chinazoliny chemická syntéza chemie farmakologie MeSH
- HIV-1 účinky léků metabolismus MeSH
- kapsida účinky léků metabolismus MeSH
- knihovny malých molekul MeSH
- látky proti HIV metabolismus farmakologie MeSH
- lidé MeSH
- molekulární modely MeSH
- rekombinantní proteiny biosyntéza MeSH
- replikace viru účinky léků MeSH
- reprodukovatelnost výsledků MeSH
- rychlé screeningové testy MeSH
- termodynamika MeSH
- viabilita buněk účinky léků MeSH
- vztahy mezi strukturou a aktivitou MeSH
- Check Tag
- lidé MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
Assembly of human immunodeficiency virus (HIV-1) represents an attractive target for antiretroviral therapy which is not exploited by currently available drugs. We established high-throughput screening for assembly inhibitors based on competition of small molecules for the binding of a known dodecapeptide assembly inhibitor to the C-terminal domain of HIV-1 CA (capsid). Screening of >70000 compounds from different libraries identified 2-arylquinazolines as low micromolecular inhibitors of HIV-1 capsid assembly. We prepared focused libraries of modified 2-arylquinazolines and tested their capacity to bind HIV-1 CA to compete with the known peptide inhibitor and to prevent the replication of HIV-1 in tissue culture. Some of the compounds showed potent binding to the C-terminal domain of CA and were found to block viral replication at low micromolar concentrations.
Chemical Biology Core Facility European Molecular Biology Laboratory 691 17 Heidelberg Germany
Department of Organic Chemistry Faculty of Science Charles University 128 43 Prague 2 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc16020081
- 003
- CZ-PrNML
- 005
- 20220614101718.0
- 007
- ta
- 008
- 160722s2016 xxu f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1021/acs.jmedchem.5b01089 $2 doi
- 024 7_
- $a 10.1021/acs.jmedchem.5b01089 $2 doi
- 035 __
- $a (PubMed)26685880
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxu
- 100 1_
- $a Machara, Aleš $u Department of Organic Chemistry, Faculty of Science, Charles University , 128 43 Prague 2, Czech Republic.
- 245 10
- $a Specific Inhibitors of HIV Capsid Assembly Binding to the C-Terminal Domain of the Capsid Protein: Evaluation of 2-Arylquinazolines as Potential Antiviral Compounds / $c A. Machara, V. Lux, M. Kožíšek, K. Grantz Šašková, O. Štěpánek, M. Kotora, K. Parkan, M. Pávová, B. Glass, P. Sehr, J. Lewis, B. Müller, HG. Kräusslich, J. Konvalinka,
- 520 9_
- $a Assembly of human immunodeficiency virus (HIV-1) represents an attractive target for antiretroviral therapy which is not exploited by currently available drugs. We established high-throughput screening for assembly inhibitors based on competition of small molecules for the binding of a known dodecapeptide assembly inhibitor to the C-terminal domain of HIV-1 CA (capsid). Screening of >70000 compounds from different libraries identified 2-arylquinazolines as low micromolecular inhibitors of HIV-1 capsid assembly. We prepared focused libraries of modified 2-arylquinazolines and tested their capacity to bind HIV-1 CA to compete with the known peptide inhibitor and to prevent the replication of HIV-1 in tissue culture. Some of the compounds showed potent binding to the C-terminal domain of CA and were found to block viral replication at low micromolar concentrations.
- 650 _2
- $a látky proti HIV $x metabolismus $x farmakologie $7 D019380
- 650 _2
- $a kapsida $x účinky léků $x metabolismus $7 D002213
- 650 _2
- $a viabilita buněk $x účinky léků $7 D002470
- 650 _2
- $a HIV-1 $x účinky léků $x metabolismus $7 D015497
- 650 _2
- $a rychlé screeningové testy $7 D057166
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a molekulární modely $7 D008958
- 650 _2
- $a chinazoliny $x chemická syntéza $x chemie $x farmakologie $7 D011799
- 650 _2
- $a rekombinantní proteiny $x biosyntéza $7 D011994
- 650 _2
- $a reprodukovatelnost výsledků $7 D015203
- 650 _2
- $a knihovny malých molekul $7 D054852
- 650 _2
- $a vztahy mezi strukturou a aktivitou $7 D013329
- 650 _2
- $a termodynamika $7 D013816
- 650 _2
- $a replikace viru $x účinky léků $7 D014779
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Lux, Vanda $u Department of Infectious Diseases, Virology, University Hospital Heidelberg , Im Neuenheimer Feld 324, 691 20 Heidelberg, Germany.
- 700 1_
- $a Kožíšek, Milan $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Grantz Šašková, Klára $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center , Flemingovo n. 2, 166 10 Prague 6, Czech Republic. Department of Biochemistry, Faculty of Science, Charles University , 128 43 Prague 2, Czech Republic.
- 700 1_
- $a Štěpánek, Ondřej $u Department of Organic Chemistry, Faculty of Science, Charles University , 128 43 Prague 2, Czech Republic.
- 700 1_
- $a Kotora, Martin $u Department of Organic Chemistry, Faculty of Science, Charles University , 128 43 Prague 2, Czech Republic.
- 700 1_
- $a Parkan, Kamil $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Pávová, Marcela $u Department of Infectious Diseases, Virology, University Hospital Heidelberg , Im Neuenheimer Feld 324, 691 20 Heidelberg, Germany. Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center , Flemingovo n. 2, 166 10 Prague 6, Czech Republic.
- 700 1_
- $a Glass, Bärbel $u Department of Infectious Diseases, Virology, University Hospital Heidelberg , Im Neuenheimer Feld 324, 691 20 Heidelberg, Germany.
- 700 1_
- $a Sehr, Peter $u Chemical Biology Core Facility, European Molecular Biology Laboratory , 691 17 Heidelberg, Germany.
- 700 1_
- $a Lewis, Joe $u Chemical Biology Core Facility, European Molecular Biology Laboratory , 691 17 Heidelberg, Germany.
- 700 1_
- $a Müller, Barbara $u Department of Infectious Diseases, Virology, University Hospital Heidelberg , Im Neuenheimer Feld 324, 691 20 Heidelberg, Germany.
- 700 1_
- $a Kräusslich, Hans-Georg, $u Department of Infectious Diseases, Virology, University Hospital Heidelberg , Im Neuenheimer Feld 324, 691 20 Heidelberg, Germany. $d 1958- $7 xx0273885
- 700 1_
- $a Konvalinka, Jan $u Institute of Organic Chemistry and Biochemistry, Academy of Sciences of the Czech Republic, Gilead Sciences and IOCB Research Center , Flemingovo n. 2, 166 10 Prague 6, Czech Republic. Department of Biochemistry, Faculty of Science, Charles University , 128 43 Prague 2, Czech Republic.
- 773 0_
- $w MED00010049 $t Journal of medicinal chemistry $x 1520-4804 $g Roč. 59, č. 2 (2016), s. 545-58
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/26685880 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20160722 $b ABA008
- 991 __
- $a 20220614101715 $b ABA008
- 999 __
- $a ok $b bmc $g 1154751 $s 944609
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 59 $c 2 $d 545-58 $e 20160106 $i 1520-4804 $m Journal of medicinal chemistry $n J Med Chem $x MED00010049
- LZP __
- $a Pubmed-20160722
